Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02546102 : Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
PhasePhase 3
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

1. Subjects must understand and sign the study specific informed consent

2. Subjects must be in primary remission

3. Subjects should have < 1 cm3 disease by MRI within the previous 4 weeks (by central

4. Subjects must be HLA-A2 positive by central lab

5. Subjects must have adequate renal, hepatic and bone marrow function based on
screening laboratory assessments. Baseline hematologic studies and chemistry and
coagulation profiles must meet the following criteria:

1. Hemoglobin (Hgb) > 8 g/dL

2. Absolute Neutrophil Count (ANC) > 1000/mm3

3. Platelet count > 100,000/mm3

4. Blood Urea Nitrogen (BUN) < 30 mg/dL

5. Creatinine < 2 mg/dL

6. Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Alanine
Aminotransferase (ALT) < 2 x upper limit of normal (ULN)

7. Prothrombin Time (PT) and activated partial thromboplastin time (PTT) ? 1.6x
unless therapeutically warranted

6. Subjects must use effective contraceptive methods during the study and for three
months following the last dose of study product, if of reproductive age and still
retain fertility potential.

7. Subjects must have at least one positive DTH skin response (more than 5 mm) to test
item challenge prior to randomization.

Exclusion Criteria:

1. Subjects receiving investigational study drug for any indication or
immunological-based treatment for any reason (Filgrastim may be used for prevention
of severe neutropenia).

2. Subjects with glioblastoma mutated IDH by Immunohistochemistry (IHC)

3. Subjects with concurrent conditions that would jeopardize the safety of the subject
or compliance with the protocol.

4. Subjects with a history of chronic or acute hepatitis C or B infection.

5. Subjects require or are likely to require more than a 2-week course of
corticosteroids for intercurrent illness. Subjects must have completed the course of
corticosteroids at the time of apheresis to meet eligibility.

6. Subjects have any acute infection that requires specific therapy. Acute therapy must
have been completed within seven days prior to study enrollment.

7. Subjects with active other malignancy diagnosed in the past 3 years (excepting in
situ tumors)

8. Subjects known to be pregnant or nursing.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557